Pharmaceutical Executive-01-01-2016

It’s easy to foresee controversy in 2016 as lagging global economic growth and a messy US political slugfest force the pharma industry’s feet to the fire. Can the industry reclaim a semblance of public approval by confronting its pricing demons and focusing on innovation and a fresh, patient-first message?

 Ferring Pharmaceuticals’ new manufacturing facility in Parsippany, NJ.  

The changing tides in the global healthcare market are showing no signs of letting up. Here's my take on the opportunities, threats, and other big issues facing the industry in the new year.

The “seven significants” for brand planning in 2016 that pose the best chance for stable footing amid the seismic state of today’s ever-changing healthcare landscape.

While the 1984 Act has been a boon for lower-cost generics, its goal of incentivizing new drug discovery has failed.

Cures remain elusive, but regulators and industry are building ties that bind.

The continuing attack on industry pricing and marketing jeopardizes coverage, R&D.

Confronted by a debt crisis and a stagnating economy, the government of Puerto Rico, the world’s fifth-largest pharma manufacturing producer, has turned to the healthcare industry-and life sciences in particular-for new sources of economic growth.

Click the title above to open the Pharmaceutical Executive January 2016 issue in an interactive PDF format.